Lung Cancer | Topics

 
Next Steps in the Management of EGFR Exon 20 Insertion–Positive mNSCLC
March 22, 2022

Closing out their discussion on mobocertinib data and the EXCLAIM cohort, experts share hope for the future management of the EGFR exon 20 insertion–positive mNSCLC.

mNSCLC: Biomarker Testing and Patient Adherence to TKIs
March 22, 2022

A brief review of biomarker testing in metastatic non–small cell lung cancer to identify alterations such as the EGFR exon 20 insertion.

EXCLAIM Cohort in mNSCLC: Treatment Selection and Management
March 14, 2022

In the context of mobocertinib clinical data, experts consider factors that help them select therapy and manage therapy for patients with EGFR exon 20 insertion–positive mNSCLC.

EXCLAIM Cohort: Mobocertinib Safety Data in mNSCLC
March 14, 2022

Focused discussion on the safety profile of mobocertinib in platinum-pretreated EGFR exon 20 insertion–positive mNSCLC given data from the EXCLAIM cohort.

Expert Commentary on the Product Profile of Amivantamab-vmjw
March 12, 2022

In an interview with ONCOLOGY®, Evan B. Bryson, PharmD, BCOP, offers a comprehensive review of real-world treatment considerations of amivantamab as therapy for patients with non–small cell lung cancer.

Efficacy Data From the EXCLAIM Cohort in mNSCLC
March 04, 2022

Shared insight on efficacy data with mobocertinib from the EXCLAIM cohort of patients with platinum-pretreated EGFR exon 20 insertion–positive mNSCLC.

Mobocertinib Use in mNSCLC: EXCLAIM Cohort Study Design
March 04, 2022

Expert oncologists review data from the EXCLAIM cohort, which analyzed mobocertinib use in platinum-pretreated patients with EGFR exon 20 insertion–positive mNSCLC.

TERAVOLT Study Identifies 7 Factors Associated with COVID-19 Mortality in Thoracic Cancer
February 22, 2022

The TERAVOLT study identified 7 factors associated with increased mortality risk for patients with thoracic malignancies who have contracted COVID-19.

Expert Commentary on the Product Profile of Mobocertinib
February 13, 2022

In an interview with ONCOLOGY®, Megan May, PharmD, BCOP, offers a comprehensive review of real-world treatment considerations of mobocertinib as therapy for patients with lung cancer.

Changes to 2021 USPSTF Lung Cancer Screening Guidelines Broaden Eligibility, Reduce Racial Disparities
February 04, 2022

The 2021 United States Preventive Services Task Force lung cancer screening criteria changes successfully reduced racial disparities in eligibility by broadening screening eligibility criteria.